The EyeArt AI eye screening system has been approved for marketing in the European Union for detecting age-related macular degeneration and glaucomatous optic nerve damage, according to a press release from Eyenuk.
The system was previously approved for diabetic retinopathy screening in the EU, making it the first autonomous AI solution with Class IIb Medical Devices Regulations CE marking for the detection of signs of diabetic retinopathy, AMD and glaucomatous optic nerve damage in patients at risk for vision loss, the release said.
The device uses retinal imaging cameras to (Read more...)